The ongoing arimoclomol clinical trial for sporadic inclusion body myositis (sIBM) continues to generate a lot of questions from our community. As part of our commitment to providing the latest information on sIBM research and clinical trials, we asked Dr. Mazen Dimachkie, Principal Investigator for the Phase II/III Arimoclomol Studies and Professor of Neurology and Director of the Neuromuscular Division at University of Kansas Medical Center, if he would provide us with an update.

Dr. Dimachkie was gracious enough to take the time to talk with Jerry Williams and Lynn Wilson. The presentation and Q&A were based on the sIBM community feedback and questions about the trial.

Watch below

What is IBM?

Learn more about inclusion body myositis (IBM) and find resources and support for IBM patients and caregivers.

What is IBM?

Who is Orphazyme A/S?

Read more about Orphazyme, a 2019 MSU sponsor, and our collaboration to help find a treatment for IBM.

Orphazyme and MSU

Check out other educational myositis videos

Tags:

Author:

Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Log in with your credentials

or    

Forgot your details?

Register for Membership

Send this to a friend